Related to Repros Gets an Extension from NIH for Deadlines Related to Lead Anticancer Agent

• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
  FDA’s recently issued guidelines pull from more than 20 years of research and clinical experience.
  
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• NIH Expects to Have New Policies for Research Using Chimpanzees Next Year
  A working group has been established to review IOM’s findings and make suggestions for implementation.
  
• As Politicos Posture, Advocates Assess the Impact of Sequestration on Federal Agencies
  NIH estimates a 7.8% cut, while FASEB projects that number could go as high as 11.1%.
  
• Gene Therapy Society Looking to NIH to Revisit Role of the Recombinant DNA Advisory Committee
  Goal is to restrict involvement in clinical trials and focus the RAC on questions of public concern.
  
• Leveraging the Cancer Transcriptome for New Drug Targets
  New analytical tools are advancing research efforts.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Harvard Professor Rides Genomics' Third Wave
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
  
• Will Less SOX2 Lead to Brain Cancer Getting Cold Feet?
  PLK1 level is elevated in glioblastoma multiforme, and its inhibition restricts the growth of brain cancer cells.
  
• Clinical Application of miRNAs Remains a Ways Off
  When and if its time comes, prognostic tests will likely be first.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• NIH Taps 25 Schools to Receive Top Dollars
  Did your alma mater make the list?
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.
  
• A Cyber War on Cancer
  New strategies are hoping to put an end to the war that Richard Nixon declared four decades ago.
  
• Chemotherapy for the 21st Century
  After a century of using body surface area, oncologists are warming to maximum-tolerated exposure for determining cancer drug dosages.
  
• Getting Cancer Immunotherapeutics Approved
  It’s not just the FDA standing in the way.
  
• 15 Breast Cancer Drugs in the Pipeline Right Now
  Which candidates are on their way from the lab to the medicine chests of thousands?
  
• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.